Phase I dose-ascending trial of Pharmacokinetics and Tolerability of single, High Doses of USL255, an Extended-Release Topiramate Formulation in Healthy Subjects

Trial Profile

Phase I dose-ascending trial of Pharmacokinetics and Tolerability of single, High Doses of USL255, an Extended-Release Topiramate Formulation in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 23 May 2014

At a glance

  • Drugs Topiramate (Primary)
  • Indications Epilepsy
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 15 Oct 2013 Results presented at the American Neurological Association's 2013 Annual Meeting.
    • 24 Jun 2013 Results will be presented at the 30th International Epilepsy Congress (IEC) in 2013.
    • 10 Dec 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top